Skip to Content


In the US, Pasireotide (pasireotide systemic) is a member of the drug class somatostatin and somatostatin analogs and is used to treat Acromegaly and Cushing's Syndrome.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Growth hormone release inhibiting hormone, GHRIH (somatostatin)

Analogue of growth hormone (somatropin)

Chemical Name

Cyclo[(4R)-4-(2-aminoetylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L-phenylalanyl-) (WHO)

Foreign Names

  • Pasireotidum (Latin)
  • Pasireotid (German)
  • PasirĂ©otide (French)
  • Pasireotida (Spanish)

Generic Names

  • Pasireotide (OS: USAN, BAN)
  • SOM 230 (IS)
  • UNII-98H1T17066 (IS)
  • Pasireotid aspartat (IS)
  • Pasireotid L-aspartat (IS)
  • Pasireotide aspartate (IS)
  • Pasireotide L-aspartate (IS)
  • SOM-230B (IS)
  • Pasireotid embonat (IS)
  • Pasireotid embonate (IS)
  • UNII-04F55A7UZ3 (IS)

Brand Names

  • Signifor
    Novartis, Bosnia & Herzegowina; Novartis, Denmark; Novartis, Croatia (Hrvatska); Novartis, Hungary; Novartis, Israel; Novartis, Poland; Novartis, Romania; Novartis, Slovakia; Novartis, Thailand; Novartis Europharm, Greece; Novartis Europharm, Slovenia; Novartis Farma, Italy; Novartis Pharmaceuticals, Canada; Novartis, Iceland; Novartis, Lithuania; Novartis, Finland; Novartis, France; Novartis, Norway; Novartis, Sweden; Novartis, United States; Novartis Pharma, Switzerland; Novartis Pharma, Germany; Novartis Pharmaceuticals UK, United Kingdom; Novartis Europharm, Austria; Novartis, France; Novartis Pharma, Germany
  • Signifor LAR
    Novartis, United States; Novartis Pharma, Switzerland


BANBritish Approved Name
ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.